Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavituximab plus paclitaxel and carboplatin in advanced NSCLC
NCT00687817Phase 2Completed
- Sponsor
- Avid Bioservices, Inc.
- Start
- Jun 2008
- Primary completion
- Jul 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bavituximab in non-small cell lung cancer (NSCLC), sponsored by Avid Bioservices, Inc. Primary endpoint: Overall Response Rate at 1 year. Started Jun 2008; status: completed.
02
Drugs
bavituximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00687817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687817.